Bayer Secures €3bn Apollo Investment in Contraceptives Business as Pharma Strategy Evolves

The deal gives Bayer additional financial flexibility while allowing the company to retain operational control of its long-acting reversible contraceptives portfolio.

Bayer has agreed a €3bn ($3.4bn) investment deal with global asset management firm Apollo, selling a minority stake in its newly established long-acting reversible contraceptives (LARC) business.

The transaction allows Bayer to unlock capital from a mature pharmaceutical asset while maintaining control over the strategic direction and operations of the business.

The agreement comes as Bayer continues to reshape its long-term pharmaceutical strategy, strengthen its balance sheet and increase investment focus on growth opportunities in specialised medicines.

Apollo Takes Minority Stake in Bayer’s Contraceptives Division

Under the agreement, Apollo will acquire a minority, non-controlling stake in Bayer’s LARC business.

The portfolio includes several of Bayer’s established contraceptive products, including:

• Mirena hormonal intrauterine system (IUD)

• Kyleena hormonal intrauterine system

• Jaydess hormonal intrauterine system

• Jadelle contraceptive implant
  

These products form part of Bayer’s wider women’s health portfolio and provide long-term pregnancy prevention options through devices designed to provide contraception over extended periods.

The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.

Despite Apollo’s investment, Bayer will retain complete operational control of the business.

The company confirmed that there will be no changes to the strategy, activities or management of the contraceptives division, which will remain part of Bayer Pharmaceuticals’ core operations.

Bayer Uses Deal to Improve Financial Flexibility

Bayer CFO Dr Judith Hartmann said the agreement will strengthen the company’s capital structure while allowing Bayer to maintain ownership and control of an important pharmaceutical business area.

The investment provides additional liquidity at a time when Bayer is managing increased financial pressures, including upcoming bond maturities and ongoing litigation costs.

The company has faced significant financial challenges following its acquisition of Monsanto in 2018, including extensive legal disputes surrounding glyphosate-based weed killer Roundup and allegations linking the product to cancer.

Bayer acquired Monsanto in a $63bn transaction, but subsequent litigation has created a long-term financial burden for the German healthcare and agriculture group.

The Apollo transaction provides Bayer with additional resources without requiring a full divestment of a profitable pharmaceutical asset.

Bayer Returns to Pharmaceutical Dealmaking

The contraceptives investment follows a renewed period of pharmaceutical deal activity for Bayer.

After a period of limited dealmaking, the company recently agreed to acquire ophthalmology specialist Perfuse Therapeutics for $2.45bn.

The acquisition gives Bayer access to a drug candidate that could potentially strengthen its ophthalmology pipeline and complement its existing position in eye care through Eylea (aflibercept), the blockbuster therapy developed with Regeneron.

Bayer has increasingly focused its pharmaceutical strategy on moving beyond older established products and expanding into specialised medicines with longer-term growth potential.

The company is targeting innovation-led growth areas while seeking to reduce reliance on legacy products.

Pharma Industry Sees Surge in High-Value Deal Activity

Bayer’s latest transaction reflects a wider trend across the pharmaceutical sector, with companies increasingly using acquisitions, licensing agreements and strategic investments to strengthen pipelines.

Pharmaceutical companies are turning to external innovation to:

• Add new medicines to development pipelines

• Access emerging technologies

• Expand into high-growth therapeutic areas

• Reduce reliance on ageing blockbuster products
  

According to GlobalData’s Pharmaceutical Intelligence Center, the total value of licensing agreements increased by 40% in the first quarter of 2026 compared with the same period in 2025.

The value of pharmaceutical acquisitions increased by 260% over the same period, highlighting a significant acceleration in healthcare dealmaking activity.

What the Apollo Deal Means for Bayer’s Future Strategy

The investment in Bayer’s contraceptives business demonstrates a growing trend among pharmaceutical companies: unlocking value from established assets while retaining strategic control.

Rather than selling the division outright, Bayer has chosen a partnership model that provides immediate capital while preserving long-term ownership of a core healthcare business.

As Bayer continues to prioritise specialised medicines and rebuild financial flexibility, further portfolio optimisation and strategic deals are likely to remain central to the company’s future growth plans.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com